Evidence map›Paper›PMID 39015157›Full record

ArticleClinical diabetes : a publication of the American Diabetes Association2024

Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study.

Elizabeth H Golembiewski, Andrea E Garcia Bautista, Eric Polley, Guillermo E Umpierrez, Rodolfo J Galindo, Juan P Brito, Victor M Montori, Janet P Gockerman, Michael Tesulov, Bertina Labatte and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical diabetes : a publication of the American Diabetes Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Elizabeth H GolembiewskiKnowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN.ORCID https://orcid.org/0000-0003-1015-3935
Andrea E Garcia BautistaKnowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN.
Eric PolleyDepartment of Public Health Sciences, University of Chicago, Chicago, IL.
Guillermo E UmpierrezDivision of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.ORCID https://orcid.org/0000-0002-3252-5026
Rodolfo J GalindoDivision of Endocrinology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL.ORCID https://orcid.org/0000-0002-9295-3225
Juan P BritoKnowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN.
Victor M MontoriKnowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN.ORCID https://orcid.org/0000-0003-0595-2898
Janet P GockermanPatient investigator, Grand Rapids, MI.
Michael TesulovPatient investigator, Rochester, MN.
Bertina LabattePatient investigator, Rochester, MN.
Mindy M MickelsonDivision of Endocrinology, Diabetes, & Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.
Rozalina G McCoyDivision of Endocrinology, Diabetes, & Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.ORCID https://orcid.org/0000-0002-2289-3183

Funding

Research Design, Data, and Analytics CoreP30DK092949 · NIDDK · UNIVERSITY OF CHICAGO · PI MILDA Renne SAUNDERS · 2011 to 2026
$10.0M
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease(ESRD) Patients with Type 2 DiabetesK23DK123384 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALINDO, RODOLFO · 2020 to 2024
$934k
NIDDK NIH HHS K23 DK123384NIDDK NIH HHS P30 DK092949
6 · The paper itself

Abstract

This mixed-methods study sought to identify pharmacotherapy preferences among 40 noninsulin-treated adults with type 2 diabetes receiving care at two U.S. health care systems. Participants ranked by relative importance various health outcomes and medication attributes and then contextualized their rankings. Most participants ranked blindness (63%), death (60%), heart attack (48%), and heart failure (48%) as the most important health outcomes and glucose-lowering efficacy (68%) as the most important medication attribute, followed by oral administration (45%) and lack of gastrointestinal side effects (38%).

Identifiers

PMID39015157
PMCPMC11247043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.